Skip to main content

Ahzantive News

Intraocular Inflammation More Common With Aflibercept Injections in Real-World Setting

FRIDAY, May 9, 2025 – The incidence of mild intraocular inflammation (IOI) in the real world occurs more frequently after intravitreal injection of aflibercept than in clinical trials, according to...

FDA Approves Ahzantive (aflibercept-mrbb), a Biosimilar to Eylea

Planegg-Martinsried, Germany July 1, 2024 – Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH (“Klinge”) jointly announce that the U.S. Food and Drug Administration (“...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Macular Degeneration, Macular Edema, Diabetic Macular Edema

Ahzantive patient information at Drugs.com